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Introduction
The hepatitis C virus (HCV) infection is still 
a relevant health public issue in Sicily, where 
live about 5 millions of citizens. Epidemiological 
studies report that in Sicily reside about 30,000 
citizens with a diagnosis of chronic hepatitis 
due to HCV. The availability of new drugs with 
direct antiviral action (DAA) is a real therapeutic 
breakthrough, but the high cost of the therapeutic 
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regimes limits their use and forced the National 
Health System to establish clinical priority for 
the treatment. 
To achieve an ethical and social project and to 
properly allocate economic resources for useful 
treatment of hepatitis C must promote the intere-
sts of the individual patient and the best benefit 
for the health organization. 
These values can be guaranteed through the 
good clinic practice, effectiveness and transparen-
cy of procedures and evidence-based therapeutic 
decisions. The pharmacological innovation has 
to be accompanied to carry forward this program 
by an important technical innovation, represented 
by the realization of modern informatics systems 
that allow to monitor patients and therapies and 
to recorder disease outcomes, which in the future 
will permit to have information to health program 
based on precision medicine1. 
The aims of the HCV Sicily Network are to 
identify patients with HCV chronic diseases who 
live in Sicily, to define the stage of disease and 
to allocate patients in the drug regimes in accor-
dance with the guidelines. In Sicily, the synergy 
between health institutions and physicians has 
been the basis for designing this new model for 
integrated management of chronic liver disease 
due to HCV infection (Figure 1). 
Materials and Methods
The HCV Sicily Network is a web-based model 
of best medical practice, which was designed 
to improve the management and the treatment 
of chronic hepatitis and cirrhosis. The Health 
Program of Sicily has predicted the networks 
integrate assistance, which through the Infor-
mation and Communication Technology (ICT) 
can improve the medical care of the citizens, 
the health efficiency and the physicians’ skills. 
The website www.registrohcvsicilia.it represents 
the communication tool, which includes citizens, 
physicians and stakeholders allowing to guaran-
tee the access to diagnosis and available antiviral 
therapies (Figure 2). The network includes 41 
centers (Figure 3) and 84 gastroenterologists or 
infectivologists connected by a web platform that 
recorded the diagnosis and the clinic priority for 
the therapy decided by AIFA (Agenzia Italiana 
del Farmaco) (Table I). 
The web platform also has an informatics 
agenda that guarantees the fibroscan booking, 
essential investigation to identify patients with 
treatment priorities and the therapies booking 
from Spoke to Hub centers, which can prescribe 
antiviral therapies. 
Results
From March 2015 to September 2016, 9,965 
patients (57% male, mean age 61 years, 34% with 
age over 70 years) have been recorded in the web 
platform. Of these 9,965 patients, 5,294 patients 
(53%) had the priority criteria for the treatment 
as defined by AIFA and 4,616 patients (32% with 
Table I. Clinical criteria for the priority treatment with DAAs defined by AIFA.
Group 1: Patients with Child-Pugh A or B cirrhosis or HCC with complete response to surgical or locoregional therapies;
Group 2: Patients with recurrent HCV hepatitis after liver transplantation;
Group 3: Patients with chronic hepatitis with severe extrahepatic manifestations HCV-related (cryoglobulinemia syndrome 
with organ damage, B-cell lymphoproliferative diseases);
Group 4: Patients with METAVIR F3 fibrosis;
Group 5: Patients on waiting list for liver transplantation because of cirrhosis and MELD score less than 25 points and/or 
HCC within Milan criteria with the possibility of a waiting list for at least 2 months;
Group 6: Patients with HCV chronic hepatitis, who received solid organ or bone marrow transplantation.
Figure 1. The key points of integrated management of HCV 
chronic diseases. 
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F3 fibrosis, 59% with Child-Pugh A cirrhosis 
and 9% with Child-Pugh B cirrhosis) started the 
therapy with DAA drugs. 
Table II reported the distribution of HCV 
genotypes and the diagnosis of liver disease 
according to age.
Figure 2. The SPOKE and HUB centers of resist - HCV. 
Figure 3. The points of clinical management of resist - HCV.
F. Cartabellotta, V. Di Marco; on behalf of of resist - HCV
14
At September 2016, 3,319 patients completed 
the treatment and 1,754 completed the 12 weeks 
of post-therapy observation (Figure 4). 
The rate of patients with F3 chronic hepatitis 
was 27.2%, 56.3% of patients had a diagnosis of 
Child-Pugh A cirrhosis and 16.9% of patients had 
a diagnosis of Child-Pugh B cirrhosis (Table III). 
By intention to treat analysis, 92.3% of treated 
patients obtained a virological response at the end of 
therapy. Only 135 patients (7.7%) didn’t obtain a viro-
logical response: 23 patients died because of liver or 
no liver-related causes, 45 were drop-out, 59 discon-
tinued the treatment because of adverse events and 
only 8 patients were virologic non-responders. The 
Sustained Virological Response (SVR) was achieved 
in 1,541 patients (87.8%), while 77 patients (4.5%) 
experienced a virological relapse during the 12 weeks 
of follow-up after the end of therapy (Figure 5).
Table II. HCV genotypes distribution and diagnosis of liver disease according with age of patients.  
 Overall Males Females Diagnosis
Age > 80 years 280 148 (53%) 132 (47%) 
Genotypes 
- 1a 8 (2.8%) 3 (2%) 5 (4%) Chronic hepatitis : 32%
- 1b  212 (75%) 115 (77%) 97 (74%) Cirrhosis: 65%
- 2 46 ( 14.4 %) 24 (16.2%) 22 (16.6%) HCC: 2%
- 3 0 0 0
- 4 4 (1.4%) 3 (2%) 1 (0.7%)
- Others/mixed  10 4 6 
Age 70- 80 years 2113 1031 (49%) 1082 (51%) 
Genotypes     Chronic hepatitis: 39.7%
- 1a 64 (3%) 25 (2.4%) 39 (3.6%) Cirrhosis: 58%
- 1b  1748 (82%) 862 (83.6%) 886 (81.8%) HCC: 2.3% 
- 2 242 (11.5%) 122 (11.8%) 120 (11%)
- 3 9 (0.4%) 5 (0.4%) 4 (0.4%)
- 4 47 (2.2%) 20 (2.0%) 27 (2.6%)
- Others/mixed  12 6 6  
Age 60- 70 years 1995 1147 (54%) 964 (46%) 
Genotypes     Chronic hepatitis: 51.3%
- 1a 124 (6.2%) 66 (5.7%) 58 (6.2%) Cirrhosis: 47.3%
- 1b  1549 (77%) 780 (68%) 769 (80%) HCC: 1.4 %
- 2 193 (9.7%) 105 (9.2%) 88 (9.3%)
- 3 41 (2%) 27 (2.3%) 14 (1.4%)
- 4 73 (3.6%) 44 (3.8%) 29 (3%)
- Other/mixed  15 9 6 
Age 50- 60 years 1516 1014 (67%) 502 (33%) 
Genotypes     Chronic hepatitis: 57%
- 1a 245 (16%) 193 (19%) 52 (10%) Cirrhosis: 42% 
- 1b  819 (54%) 484 (47%) 335 (67%) HCC: 1% 
- 2 80 (5.3%) 37 (3.6%) 43 (8.5%)
- 3 266 (17.5%) 224 (22%) 42 (8.5%)
- 4 99 (6.5%) 72 (7.2%) 27 (5.4%)
-  Others/mixed 7 4 3
Age < 50 years 1203 840 (70%) 363 (30%) 
Genotypes 
- 1a 235 (19.5%) 181 (21%) 54 (15%) Chronic hepatitis: 73%
- 1b  580 (48%) 351 (42%) 229 (63%) Cirrhosis: 26%
- 2 67 (5.5%) 44 (5.2%) 23 (6.3%) HCC: 1%
- 3 261 (21.6%) 221 (26%) 40 (15%)
- 4 51 (4.2%) 35 (4.1%) 16 (4.4%)
- Others/mixed 9  1
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Table III. Clinical features of 1.745 patients treated between March and December 2015.   
 Chronic hepatitis  Child-Pugh A cirrhosis Child-Pugh B cirrhosis
 (F3) 475 (27.2%) 983 (56.3%) 296 (16.9%) 
   
Mean age (years) 62.2 65.6 65.7
Age ≥ 70  143 (31%) 415 (42%) 133 (45%)
Men (%) 259 (56%) 573 (58%)  179 (66%)
Previous therapy (%)
- Naïve  217 (46%) 383 (39%) 131 (44.%)
- Experienced 247 (54%)  600 (61.%) 167 (56%)
Esophageal Varices (%)   364 (37.1%) 78 (26.3%)
- F0  378 (38.4%) 190 (64.2%)
- F1-F3  241 (24.5%) 30 (10%)
- not done   
Previous HCC  1 (0.2%) 26 (2.2%) 44 (14.8%)
Comorbidities  89 (19.1%) 265 (27%) 95 (32.4%)
- Diabetes  161 (34.6%) 429 (43.6%) 117 (39.5%)
- Arterial hypertension 10 (2.1%) 24 (2.4%) 14 (3.3%)
- Stage-3 kidney disease 16 (3.4%) 48 (4.6%) 11 (7.3%)
- Hearth disease  50 (10.7%) 103 (11.1%) 37(12.5%)
- Depression 
 
- HIV co-infection 29 (6.2%) 30 (4.5%) 9 (3.0%)
Genotypes (%) 50 (10.7%) 74 (7.5%) 23 (7.7%)
- 1a  318 (68.5) 726 (74%) 212 (74.6%)
- 1b  47 (10.1%) 83 (8.4%) 29 (9.8%)
- 2 21 (4.6%) 65 (6.6%) 21(7.1%)
- 3 27 (5.8%) 34 (3.4%) 12 (4.5%)
- 4 1 1 1
- Others
Figure 4. The algorithm of the patients included in the resist - HCV.
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Discussion
The EASL and AASLD guidelines2,3 recom-
mended therapy with DAAs for all patients with 
a chronic liver disease related to HCV infection, 
but in Italy, the AIFA indicated some clinical pri-
ority criteria for the treatment of patients. 
The HCV Sicily Network is a web-based model 
that consents the transparent and appropriation 
management of therapy with DAAs as indicate 
by AIFA and provides real-time results to the 
regional health organization and the scientific 
community. 
The HCV Sicily Network is an extraordinary 
system for the Regional Department of Health 
that can have a real estimation of patients that 
received an efficacy, but high-cost therapy. 
This network provides with high precision 
and continually all the data on the efficacy 
and tolerability of antiviral therapies in a very 
large cohort of patients treated in all centers of 
Sicily. At the same time continue the follow-up 
of patients who have not the priority for the 
treatment criteria.
Conclusions
The work will consent to upload also the epide-
miologic estimates of virus C infections in Sicily 
and to evaluate the natural disease history in the 
next years to the light of eradication obtained 
with new DAAS.
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Figure 5. The results (End of Treatment Response and Sustained Virological Response) of therapy in patients who conclu-
ded the therapy and follow-up (Intention to treat analysis).
